Endeavor Venture Funds Partner and CIO, Dr. Martin Gershon, Joins Pepper Bio As Senior Advisor

Pepper Bio, the world’s first transomics drug discovery company, announced the addition of Dr. Martin Alexander Gershon to its team as a senior advisor. Dr. Gershon, the managing partner and CIO of Endeavor Life Sciences Venture Funds and Senior Investor-in-Residence for Techstars NY powered by JPMorgan, will support Pepper Bio’s strategic growth and partnership initiatives.

Pepper Bio’s platform, COMPASS, integrates genomic, transcriptomic, proteomic, and phosphoproteomic data to provide researchers with a global, causal, and functional understanding of biological processes and functions. By harnessing the combined powers of AI, computational biology, and mathematical analysis, Pepper Bio provides the critical insights that help researchers determine if a drug or target will succeed before the costly clinical trial stage.

Indicative of the company’s early success, this year Pepper Bio inked partnerships with two top-10 global pharma companies, raised seed funding led by NFX & Merck, built out its internal pipeline, and published research showcasing the value of transomics.

In addition, as Chairperson and moderator for several AI and Drug Discovery Conferences in 2023, Dr. Gershon is in a unique position to see the decision-making perspectives of institutional and corporate investors and industry leaders from Fortune 500 companies. Dr. Gershon states, “It was evident that Investors and Industry Leaders want two things from Founders: 1. Commercial validation that comes from the establishment of strategic partnerships and projects that verify commercial viability and product-market fit; and 2. Strong teams that can execute and deliver results and compelling data that defines the use cases and value of the technology.”

Dr. Gershon is a former Harvard and Columbia-trained neuroscientist, oncologist, immunologist, FDA attorney, and Ivy League professor. Over the past 23 years, Dr. Gershon has founded and exited six startups, raised over $1B, and led 105 investments at Endeavor, including investments in Moderna and Grail. His advisory expertise spans Fortune 500 companies like McKinsey, Goldman Sachs, Bain Capital, BlackRock, Bristol-Myers Squibb, and more.

Since founding Endeavor Life Sciences Ventures in 2009, Dr. Gershon is credited for developing its thriving ecosystem of partnerships with biopharma companies, startup accelerators, and Ivy League universities like Harvard, MIT, and Johns Hopkins. Additionally, he serves as the Senior Executive Investor-in-Residences and Lead Mentor for Techstars, a pre-seed investment company that supports early-stage entrepreneurs.

“Dr. Gershon’s expertise will be immensely valuable to Pepper Bio as we start our next phase of growth,” said Jon Hu, the CEO and co-founder of Pepper Bio. “His track record attests to the impact that he’s had on other early-stage companies, especially investments for AI in drug discovery and rare diseases. His passions and experience align with our mission to end untreatable diseases, and together, I believe we can achieve that.”

To learn more about Pepper’s transomic platform or to explore partnership opportunities, visit: Pepper.bio.

About Pepper Bio
Pepper Bio is the world’s first transomics drug discovery company, leveraging its proprietary transomics database and analytics to identify promising first-in-class therapies, rediscover new uses for existing therapeutics, and rescue drugs in development on a path toward failure. Founded in 2020 and based in Boston, Massachusetts, Pepper Bio is led by co-founder and Chief Executive Officer, Jon Hu, and co-founder and Chief Science Officer, Samantha Dale Strasser, Ph.D.

Contact Information

Melissa Mowery

PR for Pepper Bio

VSC for Pepper Bio

Contact via E-mail